<DOC>
	<DOC>NCT00493324</DOC>
	<brief_summary>A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.</brief_summary>
	<brief_title>Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis</brief_title>
	<detailed_description>This is a 1 arm study designed to evaluate the immune response to pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subject has chronic plaque psoriasis Subject has at least 5% body surface area affected with psoriasis Skin disorder other than plaque psoriasis in affected area Previously immunized with any pneumococcal vaccine Subject has pustular or erythrodermic psoriasis Subject is immunocompromised Six or more herpes simplex virus outbreaks per year History or malignancy, chronic serious infection or hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>alefacept</keyword>
	<keyword>polyvalent pneumococcal vaccine</keyword>
	<keyword>Immunization</keyword>
</DOC>